Logo

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

Share this

Atea Pharma Secures $50M Milestone Payment with Roche in the Development of AT-527 for COVID-19

Shots:

  • Atea Pharma achieved a milestone related to the development of AT-527 and is expecting to receive a related payment of $50M under its license agreement with Roche. The company believes that AT-527 is suitable for use in both pre-and post-exposure prophylactic settings and complementary to vaccines
  • The companies are jointly developing AT-527 for the treatment of COVID-19 where Atea retains commercialization rights for AT-527 in the US and Roche holds the exclusive right to commercialize AT-527 outside of the US
  • AT-527 is currently being evaluated in the global P-III MORNINGSKY trial- P-II study for hospitalized patients with moderate COVID-19- and a P-II outpatient study in patients with mild or moderate COVID-19

  Ref: Globe Newswire | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions